This is a preview of subscription content, log in via an institution to check access.
References
Sundaresan PR, Shah A, Woodruff M, et al. Safety and pharmacokinetics of BAY 12-9566, a metalloproteinase inhibitor in middle-aged and elderly subjects. Clin Pharmacol Ther 1998 Feb; 63: 169
Shah A, Sundaresan P, Humphrey R, et al. Comparative pharmacokinetics of BAY 12-9566, a metallo-proteinase inhibitor, in healthy volunteers and cancer patients. 89th Annual Meeting of the American Association for Cancer Research; 1998 Mar 28–Apr 1; New Orleans. Philadelphia: American Association for Cancer Research, 1998: 521
Grochow L, O’Reilly S, Humphrey R, et al. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor, BAY12-9566 [abstract 213]. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16–19; Los Angeles
Grochow LB. Preclinical and clinical pharmacology of matrix metalloproteinase inhibitors. Ann Oncol 1998; 9 Suppl. 2: 11
Gatto C, Rieppi M, Borsotti P, et al. Anti-angiogenic activity of BAY 12-9566, an inhibitor of matrix metalloproteinases. Ann Oncol 1998; 9 Suppl. 2: 74
Hibner B, Bull C, Flynn C, et al. Activity of the matrix metalloproteinase inhibitor BAY 12-9566 against murine subcutaneous and metastatic in vivo models. Ann Oncol 1998; 9 Suppl. 2: 75
Nozaki S, Sissons S, Casazza AM, et al. Inhibition of human breast cancer regrowth and pulmonary metastases by BAY 12-9566 in athymic mice. 89th Annual Meeting of the American Association for Cancer Research; 1998 Mar 28–Apr 1; New Orleans. Philadelphia: American Association for Cancer Research, 1998: 301
Rights and permissions
About this article
Cite this article
BAY12-9566. Drugs R&D 1, 142–143 (1999). https://doi.org/10.2165/00126839-199901020-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901020-00006